Immune remodelling and molecular profiling of progressive brain metastases following cranial radiotherapy
Open Access
- 13 August 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 246, 116988
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Peripheral blood DNA methylation profile and immune checkpoint inhibitor response in cancer patientsESMO Open, 2026
- Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 studyThe Lancet Oncology, 2025
- Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 yearsEuropean Journal of Cancer, 2022
- Brain metastases in metastatic cancer: a review of recent advances in systemic therapiesExpert Review of Anticancer Therapy, 2020
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsThe Lancet Oncology, 2016
- High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironmentBritish Journal of Cancer, 2014
- Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012European Journal of Cancer, 2012
- Plasticity of Foxp3+ T Cells Reflects Promiscuous Foxp3 Expression in Conventional T Cells but Not Reprogramming of Regulatory T CellsImmunity, 2012
- Macrophages join the FOXP3 suppressor gangNature Reviews Immunology, 2011
- Adjusting for multiple testing—when and how?Journal of Clinical Epidemiology, 2001